For instance, some trials revealed that atorvastatin does not reduce CRP levels in T2DM patients [17,18,19,20], while other studies do not confirm whether the baseline CRP concentration influences the vascular benefits of statin therapy [21,22]. This evidence concerns the gene CRP and type 2 diabetes mellitus.